Consistent with the results of tumor growth, xenografted mice treated with 161519 TriKE showed significantly improved survival compared with that of the control and 1619-BiKE treatment groups (P < 0.01 for both) (Figure 5D), which suggested the potential value of 161519 TriKE in treating CD19+ tumors in vivo. This evidence concerns the gene CD19 and neoplasm.